SecSonar.com

Geron Corporation (GERN)

Geron Corporation at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Geron Corporation (GERN) is a Biotechnology company based in US with a market capitalization of $805.1M. Revenue grew 138.8% year-over-year and free cash flow was negative at -$111.1M. This page tracks GERN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 229 employees · IPO Jul 31, 1996

Valuation

Valuation & price

$1.29 · as of May 17, 2026 · -33.8% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

3.56

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$1.95$1.52$1.08Jul 25Dec 25Jul 26Jul 7, 25$1.37Jul 9, 25$1.44Jul 11, 25$1.32Jul 15, 25$1.26Jul 17, 25$1.29Jul 21, 25$1.23Jul 23, 25$1.33Jul 25, 25$1.26Jul 29, 25$1.14Jul 31, 25$1.15Aug 4, 25$1.21Aug 6, 25$1.39Aug 11, 25$1.36Aug 13, 25$1.43Aug 15, 25$1.45Aug 19, 25$1.43Aug 21, 25$1.43Aug 25, 25$1.42Aug 27, 25$1.41Aug 29, 25$1.40Sep 3, 25$1.40Sep 5, 25$1.40Sep 9, 25$1.36Sep 11, 25$1.32Sep 16, 25$1.25Sep 18, 25$1.32Sep 22, 25$1.33Sep 24, 25$1.33Sep 26, 25$1.29Sep 30, 25$1.37Oct 2, 25$1.38Oct 6, 25$1.28Oct 8, 25$1.38Oct 10, 25$1.31Oct 14, 25$1.24Oct 16, 25$1.23Oct 21, 25$1.27Oct 23, 25$1.22Oct 27, 25$1.28Oct 29, 25$1.23Oct 31, 25$1.26Nov 4, 25$1.15Nov 6, 25$1.08Nov 10, 25$1.16Nov 12, 25$1.24Nov 14, 25$1.12Nov 18, 25$1.11Nov 20, 25$1.10Nov 25, 25$1.16Nov 28, 25$1.18Dec 2, 25$1.23Dec 4, 25$1.27Dec 8, 25$1.27Dec 10, 25$1.28Dec 12, 25$1.36Dec 16, 25$1.34Dec 18, 25$1.34Dec 22, 25$1.35Dec 24, 25$1.40Dec 29, 25$1.37Jan 2, 26$1.32Jan 6, 26$1.32Jan 8, 26$1.37Jan 12, 26$1.43Jan 14, 26$1.35Jan 16, 26$1.31Jan 21, 26$1.34Jan 23, 26$1.38Jan 27, 26$1.38Jan 29, 26$1.37Feb 2, 26$1.54Feb 4, 26$1.47Feb 9, 26$1.61Feb 11, 26$1.61Feb 13, 26$1.65Feb 18, 26$1.94Feb 20, 26$1.88Feb 24, 26$1.95Feb 26, 26$1.65Mar 2, 26$1.55Mar 4, 26$1.47Mar 6, 26$1.53Mar 10, 26$1.63Mar 12, 26$1.60Mar 17, 26$1.62Mar 19, 26$1.55Mar 23, 26$1.54Mar 25, 26$1.57Mar 27, 26$1.40Mar 31, 26$1.49Apr 2, 26$1.66Apr 7, 26$1.74Apr 9, 26$1.76Apr 13, 26$1.73Apr 15, 26$1.69Apr 17, 26$1.68Apr 22, 26$1.55Apr 24, 26$1.50Apr 28, 26$1.51Apr 30, 26$1.54May 4, 26$1.57May 6, 26$1.58May 8, 26$1.39May 12, 26$1.40May 14, 26$1.40May 18, 26$1.23May 20, 26$1.26May 22, 26$1.28May 28, 26$1.25Jun 1, 26$1.21Jun 3, 26$1.16Jun 5, 26$1.17Jun 9, 26$1.12Jun 11, 26$1.14Jun 15, 26$1.15Jun 17, 26$1.23Jun 22, 26$1.34Jun 24, 26$1.39Jun 26, 26$1.32Jul 2, 26$1.36
$1.0752-week range$1.95
Loading valuation history…

Fundamentals

Key fundamentals

$805.1M

Market cap

138.8%

Revenue growth (YoY)

97.4%

Gross margin

-$111.1M

Free cash flow (USD)

-$108.2M

Net debt

Net cash position

3.2%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$6.2MFY 2017$1.1MFY 2018$1.1MFY 2019$460.0KFY 2020$253.0KFY 2021$1.4MFY 2022$596.0KFY 2023$237.0KFY 2024$77.0MFY 2025$183.9M
$6.2M$183.9M

Free cash flow by year

2016 → 2025

FY 2016$-18.4MFY 2017$-20.6MFY 2018$-21.0MFY 2019$-44.2MFY 2020$-67.1MFY 2021$-95.8MFY 2022$-127.8MFY 2023$-168.6MFY 2024$-219.3MFY 2025$-111.1M
-$18.4M-$111.1M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 202498.4%FY 202597.4%
100.0%97.4%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventEquity Incentive Plan AmendmentMay 27, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing

Questions

Frequently asked questions

What is Geron Corporation's market cap?

Geron Corporation (GERN) has a market capitalization of $805.1M.

What is GERN's P/E ratio?

A meaningful P/E ratio is not available for GERN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is GERN's price-to-book (P/B) ratio?

GERN trades at 3.56 times book value per share.

Are insiders buying GERN stock?

SEC Form 4 filings show no open-market insider buys at Geron Corporation in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

PHAT

Phathom Pharmaceuticals, Inc.

$788.3M

ZBIO

Zenas BioPharma, Inc.

$829.2M

ETON

Eton Pharmaceuticals, Inc.

$834.6M

TBPH

Theravance Biopharma, Inc.

$835.7M

XNCR

Xencor, Inc.

$885.3M

JANX

Janux Therapeutics, Inc.

$894.3M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.